CRSP Operating Cash Flow (Statement)
Crispr Therapeutics Ag · Operating Cash Flow (Statement)
CRSP Operating Cash Flow (Statement)
Latest reported-$369.58Mperiod ending
CRSP TTM Cash from Operations ($59.43M → -$369.58M)
TTM operating cash flow (statement)
High-resolution chart · PNG
CRSP operating cash flow (statement) history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Operating Cash Flow (Statement) (USD) |
|---|---|
| -369,582,000 | |
| -399,964,000 | |
| -345,014,000 | |
| -302,492,000 | |
| -324,771,000 | |
| -306,473,000 | |
| -142,774,000 | |
| -188,816,000 | |
| -121,759,000 | |
| -159,422,000 | |
| -260,375,000 | |
| -277,630,000 | |
| -342,992,000 | |
| -351,703,000 | |
| -495,741,000 | |
| -468,451,000 | |
| -444,562,000 | |
| 504,396,000 | |
| 538,972,000 | |
| 543,798,000 | |
| 549,427,000 | |
| -286,854,000 | |
| -238,366,000 | |
| -153,778,000 | |
| 55,342,000 | |
| 48,239,000 | |
| 56,677,000 | |
| 24,929,000 | |
| -128,455,000 | |
| -117,288,000 | |
| -96,239,000 | |
| -82,709,000 | |
| -78,613,000 | |
| -69,373,000 | |
| -70,097,000 | |
| -74,671,000 | |
| -71,079,000 | |
| -68,708,000 | |
| -55,310,000 | |
| 33,110,000 | |
| 40,073,000 | |
| 50,997,000 | |
| 59,428,000 |